HighTide Therapeutics Inc
Company Profile
Business description
HighTide Therapeutics Inc is a biopharmaceutical company specializing in the discovery, development and commercialization of multifunctional, multi-targeted therapies for the treatment of metabolic and digestive diseases. The company has developed a product pipeline of five product candidates in-house, covering nine indications in metabolic and digestive diseases among which, five are at clinical-stage. The Core Product, HTD1801 (berberine ursodeoxycholate), a new molecular entity, is a gut-liver anti-inflammatory metabolic modulator which targets multiple pathways pivotal to metabolic regulation, including those associated with metabolic and digestive diseases.
Contact
Ganli Second Road
18B-102, Zhonghaixin Innovation Industry City
Jihua Neighborhood
Longgang District, Guangdong
Shenzhen518112
CHNSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
70
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,704.40 | 143.20 | -1.82% |
| CAC 40 | 7,158.91 | 231.79 | 3.35% |
| DAX 40 | 20,401.12 | 611.50 | 3.09% |
| Dow JONES (US) | 37,822.40 | 2,723.53 | -6.72% |
| FTSE 100 | 7,966.86 | 88.12 | -1.09% |
| HKSE | 20,127.68 | 2,722.13 | -11.91% |
| NASDAQ | 15,603.26 | 947.34 | -5.72% |
| Nikkei 225 | 33,012.58 | 768.00 | -2.27% |
| NZX 50 Index | 11,891.44 | 333.84 | -2.73% |
| S&P 500 | 5,041.94 | 20.31 | -0.40% |
| S&P/ASX 200 | 7,510.00 | 157.80 | -2.06% |
| SSE Composite Index | 3,145.55 | 48.97 | 1.58% |